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Abstract
Background: Caesarean section of bitches is a well recognized painful condition in dogs and it can be classified as
a soft tissue surgery. Cimicoxib, a newly registered NSAID in European Union has a claim for the relief of pain in
peri-operative conditions. However, in case of caesarean section, the main concerns of using NSAIDs are the
transfer of the drugs into milk and its impact on the suckling pups. Thus, the aim of the present work was
to evaluate the transfer of cimicoxib into the milk of 6 lactating bitches after a single oral administration of
the drug on day 0 (just after whelping) and on day 28 at the target dose of 2 mg/kg. Another aim of the
study was to evaluate the transfer of the drug from the milk into the suckling pups. Blood and milk samples
were collected from the bitches after each administration on day 0 and day 28 and blood samples were
drawn from the pups after suckling on day 28.
Results: All bitches whelped without any complication and gave birth to 38 pups. After administration on D0, the
mean observed plasma Cmax in bitches was 0.5323 μg/mL and the mean area under the concentration-time curve
extrapolated to the infinity, AUCINF, was 2.411 μg.h/mL. After administration on D28, only AUCINF was significantly
higher with a value of 3.747 μg.h/mL. In milk, after administration on D0, the mean observed Cmax was 0.9974 μg/mL
and the mean area under the concentration-time curve until the last measurable time point, AUClast, was 4.205 μg.h/
mL. Out of 24 sampled pups on D28, only 2 animals had a sample with very low cimicoxib concentrations slightly
above the limit of quantification (0.01 μg/mL).
Conclusion: The presented data show that cimicoxib given by oral route to lactating bitches at a single dose of 2 mg/
kg had a high transfer rate into the milk with a milk to plasma ratio of 1.7 to 1.9. The transfer rate to the suckling pups
was low and no clinical abnormalities were detected in both bitches and pups.
Background
Caesarean section of bitches is a well recognized painful
condition in dogs [1]. It can be classified as a soft tissue
surgery like ovariohysterectomy. In order to relief pain
in peri-operative conditions, NSAIDs proved to be much
helpful. Several NSAIDs are approved for the treatment
of peri-operative pain in dogs and cimicoxib, a newly
registered drug in European Union, has such a claim.
However, in case of caesarean section, treatment of post-
operative pain with NSAIDs is not a common practice.
The main concerns of using NSAIDs are the transfer of
the drugs into milk and its impact on the suckling pups
[1]. At present, studies evaluating the transfer of
NSAIDs into the milk of bitches are not published. The
excretion of NSAIDs into milk was essentially studied in
dairy cows in order to calculate withdrawal periods for a
consumer protection purpose [2–5]. The excretion rates
of these drugs into milk are generally quite low [2–5].
However, excretion of selective COX-2 inhibitors (coxib)
in dairy milk is not described as these drugs are not yet
approved in food animals. Coxibs being more lipophilic
than classical NSAIDs [6], their excretion rate into milk
might be higher.
In human medicine, NSAIDs are regularly used for the
treatment of post-operative pain after elective or un-
scheduled caesarean section [7–11]. Use of these drugs
is associated with faster recovery and lower require-
ments of opioid drugs [12–16]. The excretion of coxibs
into human milk was studied with parecoxib [17]. The
obtained milk concentrations of parecoxib and its active
metabolite valdecoxib were quite low resulting in low
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exposure rates of the suckling children. The authors con-
cluded that the administration of parecoxib to lactating
women after cesarean delivery is unlikely to cause adverse
effects in breastfed infants.
Thus, the main aim of the present study was to pro-
vide some information regarding the transfer of cimi-
coxib into the milk of bitches for the potential use of the
drug in post-caesarean pain relief. The second aim of
the study was to evaluate the transfer of the drug from
the milk into the suckling pups.
Results
All 6 bitches whelped without any complication and
gave birth to 38 pups. The bitches were dosed suc-
cessfully on study day 0 and 28 with no post-dosing
vomiting. All bitches lost weight (range of weight loss
was 0.5 – 3.8 kg) from study day 0 until study day
29. A decrease in bodyweight is not unexpected with
lactating bitches. All pups were still alive on day 7
and they gained bodyweight from study day 7/8 to
study day 29. On day 19, one pup was missing and
was presumed to have been eaten by its mother. For
all other pups, no abnormalities were detected during
the scheduled veterinary examinations or clinical as-
sessments. Cimicoxib was well tolerated in the bitches
and in the pups throughout the study.
Mean concentration-time profiles of cimicoxib in
plasma and in milk of the bitches are presented in Fig. 1.
After administration on D0, the mean observed plasma
Cmax was 0.5323 μg/mL (sd = 0.08694 μg/mL) and the
mean observed occurrence time of the Cmax, Tmax, was
2.83 h (sd = 1.33 h). The mean terminal half-life, T½λz,
was 1.47 h (sd = 0.31 h). The mean area under the
concentration-time curve extrapolated to the infinity,
AUCINF, was 2.411 μg.h/mL (sd = 0.9771 μg.h/mL). The
extrapolated part was low with a mean value of 3.14 %
(sd = 1.41 %). The total clearance, Cl_F, was 0.8896 L/
h.kg (sd = 0.2575 L/h.kg). The mean residence time ex-
trapolated to the infinity, MRTINF, led to a mean value
of 4.11 h (sd = 1.48 h). After administration on D28, the
mean observed Cmax was 0.6692 μg/mL (sd = 0.3088 μg/
mL) which was not statistically higher than after admin-
istration on D0. The mean observed Tmax was 2.67 h
(sd = 1.03 h) which was close to the value obtained on
D0 and not statistically different. The mean terminal
half-life, T½λz, was 2.15 h (sd = 0.59 h) which was some-
what longer than after administration on D0, but the dif-
ference was not statistically significant. The mean
AUCINF was 3.747 μg.h/mL (sd = 1.821 μg.h/mL). The
extrapolated part was still low with a mean value of
4.22 % (sd = 3.05 %). The AUCINF value was statistically
higher (p = 0.039) than the mean value obtained on D0.
The total clearance, Cl_F, was 0.5867 L/h.kg (sd =
0.1472 L/h.kg) and was statistically lower (p = 0.031)
than the clearance calculated on D0. The mean MRTINF
was 5.15 h (sd = 1.39 h).
In milk, after administration on D0, the mean ob-
served Cmax was 0.9974 μg/mL (sd = 0.250 μg/mL) which
was about twice the value obtained in plasma on D0.
The mean Tmax, was 3.17 h (sd = 1.33 h). The mean area
under the concentration-time curve until the last meas-
urable time point, AUClast, was 4.205 μg.h/mL (sd =
Fig. 1 Mean concentration-time profiles of cimicoxib (semi-logarithmic scale) in plasma and milk of 6 bitches after a single oral tablet administration
of a dose of 2 mg/kg (range 1.4 to 2.6 mg/kg) given just after whelping (D0) and 28 days later (D28). On D28, the milk concentration corresponds to
the average out of 6 values for the time point of 1 h, out of 5 values for the time points of 2 and 4 h and out of 3 values for the time point of 8 h
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1.534 μg.h/mL). This value was also about twice the
value obtained in plasma on D0. The mean residence
time until the last measurable time point, MRTlast was
3.25 h (sd = 0.85 h). After administration on D28, milk
samples could not be collected at every time point for all
bitches because they produced much less milk than on
D0. As the missing time points were located in the last
elimination phase, only the observed Cmax and the Tmax
could be obtained in the milk samples. The mean ob-
served Cmax was 1.146 μg/mL (sd = 0.2683 μg/mL) and
the mean observed Tmax was 3.00 h (sd = 1.10 h) which
was close to the value obtained on D0.
For the pups, the time lapse between suckling and the
first blood collection time point (1.5 h post bitch dosing)
ranged from 20 to 29 min. Out of 24 sampled pups, only
2 animals had a plasma sample with very low cimicoxib
concentrations, slightly above the limit of quantification.
Both samples were taken 8.5 and 24 h after dosing the
bitch. In the plasma samples of all the other puppies, the
concentration of cimicoxib remained below the limit of
quantification. Thus, although cimicoxib reached high
concentrations in the milk of the bitches, the amount
taken and/or absorbed by the pups is quite low.
Discussion
To the best of our knowledge, this is the first report on
excretion of NSAIDs into dog milk and on subsequent
concentrations reached in suckling pups. Pharmacokin-
etics of cimicoxib were also described in other monogas-
tric species: horses [18] and donkeys [19]. Compared to
published pharmacokinetic data in dogs [20], the bitches
in the present study could seem extensive metabolising
animals. Indeed, the obtained terminal half-lives in plasma
for days 0 and 28 were within a range of 1.09 to 2.97 h,
whereas the mean terminal half-life in “poor metabolizers”
was 8.0 ± 0.6 h [20]. The obtained mean terminal half-live
on D0 (1.47 h) was even somewhat lower than the pub-
lished value (2.9 h). The mean value obtained on D28
(2.15 h) was closer to the published value. Terminal half-
life is a hybrid parameter depending both on volumes of
distribution and on total body clearance. Lactation is
known to modify both parameters with an increase in vol-
ume of distribution and/or an increase in clearance [21].
However, the most often encountered situation is an in-
crease in total body clearance during early lactation [22]
and hence a decrease in terminal half-life of drugs. This
latter situation seems to be the case in our study on D0
because the mean clearance obtained, 0.8896 L/h.kg, is
about two times higher than the clearance of non lactating
dogs, 0.4959 L/h.kg [23]. At a later lactation stage on D28,
the terminal half-life was increased almost significantly (p
= 0.067) while AUCINF values were also significantly in-
creased (p = 0.039). This increase of exposure to cimicoxib
may be explained only by a decrease of the total body
clearance confirming that the shorter terminal half-life at
early lactation was the result of an increased clearance on
D0. The Cmax and Tmax values obtained in whelping
bitches in the present study on D0 were close to published
values in “normal” beagle dogs [23]. However, terminal
half-life and AUCINF values were lower in the present
study which reinforces the clearance hypothesis.
The measured concentrations of cimicoxib in the bitch
milk are higher than the concentrations measured in
plasma leading to quite high milk to plasma concentra-
tion ratios of 1.7 to 1.9. Thus, cimicoxib seemed to be
concentrated in the milk contrary to what was observed
for parecoxib in human medicine [17]. This behaviour
difference between the two drugs may be explained by
the lipophilic nature of the drugs and by the milk com-
position. Dog milk contains about 10 % fat [24] whereas
human milk contains about 3 to 5 % fat [25, 26]. The
higher fat content of dog milk may increase the transfer
rate of lipophilic drugs relative to human milk. There-
fore, it might explain why the obtained milk to plasma
concentrations ratio of cimicoxib in dog milk was higher
than the ratio obtained with parecoxib in human milk.
Concerning parecoxib, the volume of distribution of the
drug in the dog was about 0.09 L/kg [27] which reflects
a distribution essentially within body water. Its main ac-
tive metabolite, valdecoxib, has a volume of distribution
of about 0.9 L/kg [28] which is 10 times higher than its
prodrug but still lower than the volume of distribution
of cimicoxib which is about 1.1 L/kg [20]. As the volume
of distribution of parecoxib is lower than the volume of
distribution of cimicoxib, its transfer rate into the milk
should be lower [21].
Despite these high milk to plasma concentration ra-
tios, the intake of cimicoxib by the puppies seems to be
very low. Indeed, cimicoxib concentration in the pups
on D28 was below or slightly above the lower limit of
quantification (0.01 μg/mL). In order to evaluate the
dose of cimicoxib taken by the pups, a worst case sce-
nario was considered. The Cmax of cimicoxib in milk on
D28 (1.146 μg/mL) was taken together with the average
milk intake of the puppies. In the present study, this
value was not measured; however, Oftedal [24] evaluated
a mean milk intake of 175 g in 26 days old beagle pup-
pies. Thus, as age of the puppies was very close to the
age of the puppies in our study (28 days), this intake
value was taken as a basis for our evaluation. Subse-
quently, the mean intake was calculated to be 201 μg of
cimicoxib, assuming that the density of dog milk is close
to 1. The mean weight of the pups in our study was
1.11 kg (sd = 0.23 kg) which is close to the weight of the
pups in the manuscript of Oftedal [24]. The maximal
cimicoxib dose taken by the pups was 0.18 mg/kg which
is about 10 times lower than the dose administered to
the bitches. Pups were not weighed on D0 in our study
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and therefore, estimation of the dose of cimicoxib taken
after suckling is not straightforward. However, based on
literature data [24, 29] a weight of 0.239 kg and a mean
milk intake of about 100 g may be considered. Taking
into account the Cmax of cimicoxib in milk on D0,
0.9974 μg/mL, a maximal dose of about 0.42 mg/kg can
be estimated. This dose is higher than the dose taken on
D28, but it remained quite low.
Conclusion
The presented data show that cimicoxib given by oral
route to lactating bitches at a dose of 2 mg/kg had a
high transfer rate into the milk with a milk to plasma ra-
tio of 1.7 to 1.9. Twenty eight days old puppies suckling
the milk from the dams treated with this single 2 mg/kg
oral dose had plasma cimicoxib concentrations below or
very close to the limit of quantification (0.01 μg/mL).
Thus, the data obtained in the present work suggests
that after administration of a single clinical dose of cimi-
coxib to whelping bitches, suckling puppies should be
minimally exposed to the drug through the dam’s milk
and no serious adverse effect should occur.
Methods
Animals and housing
Cimicoxib was given to 6 bitches shortly after whelping
(D0) and the transfer of the drug into the milk of the
dams was evaluated. The treatment was repeated about
one month after whelping (D28) and the disposition of
cimicoxib was evaluated again in the bitches as well as
in their pups after suckling. The general study design is
described in Table 1 and was approved by the Charles
River Laboratories Preclinical Services Ireland Ethical
Committee which has the authorization number AE19108.
Six Beagle bitches from the breeding colony of Charles
River Laboratories Preclinical Services at a late preg-
nancy stage weighing 10.8 to 18.7 kg were used and they
were about 5 to 8 years old. Each bitch was enrolled
onto the study when she gave birth to pups. Bitches
were housed individually in pens measuring 4.0 m x
1.1 m (l x w). Inside each pen, a resting area with rubber
matting was provided for each bitch. The pen was di-
vided into two sections by a division down the middle.
The dividing section had a gate to allow the animal ac-
cess to both halves of the pen. The gate was used to sep-
arate the bitch from her pups when necessary. In each
pen there was a whelping box measuring approximately
1.1 m x 0.7 m (l x w). An infra-red lamp was added at
the time of whelping to provide a supplementary source
of heat. After whelping, each pen housed 1 bitch and
her litter. Bitches were fed with about 350 g/day with a
specific dry food (Gilpa Trinkets, Gilbertson & Page ltd,
UK). Pups were fed by suckling the milk of their dam.
Bitches were administered 1 or ½ 30 mg Cimalgex®
tablet leading to an actual dose range of 1.4 to 2.6 mg/
kg with a target dose of 2 mg/kg. Cimalgex® tablets were
manufactured by Vétoquinol SA. The bitches were dosed
once on study day 0 about 1 h after birth of the last pup.
The technician assisting the birth of puppies assessed if
the bitch had finished whelping by manual palpation.
Bitches were fed after dosing on day 0 or at most 5 h be-
fore dosing. Bitches were dosed again once on day 28
before the pups were suckling. The bitches were fed
after dosing on day 28.
On day 0 and day 28, all bitches were carefully ob-
served for adverse events. Clinical assessments were car-
ried out by a trained technician/veterinarian. Clinical
assessments were performed prior to dosing and at 1.5 h
± 15 min post-dosing. The following parameters were
assessed: behaviour, respiration, salivation/vomit, nervous
signs, locomotion/musculature and faeces. When faeces
were present, they were removed from the pen after each
assessment. In addition, general health observations were
carried out from day 0 to day 29.
On day 7 (±24 h), all pups that had survived, were
microchipped, weighed and examined by a veterinarian.
The pups from each litter that presented any evidence of
illness at the veterinary examination were not qualified
for participation. All the other pups which were consid-
ered as healthy were enrolled onto the study on day 7
(±24 h). General health observations were carried out
throughout the study from day 7 to day 29.
Sampling
Blood samples of 3 mL were collected post dosing (on
days 0–1 and 28–29) from the jugular vein of the bitches
Table 1 Experimental design
Study days
D0 D1 D7 D27 D28 D29
Body weight bitches - - - bitches, pups -
Clinical assessment bitches - pups - bitches -
Drug administration bitches - - - bitches -
Blood sampling bitches bitches - pups bitches, pups bitches, pups
Milk sampling bitches bitches - - bitches bitches
-: not applicable
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in tubes containing lithium heparin on the following
time points: 0.5, 1, 2, 4, 6, 8, 10 and 24 h. A sample was
also taken pre-treatment before whelping. Blood samples
of 1 mL were collected (on days 28 and 29) from the
jugular vein of the pups on the following time points:
1.5, 4.5, 8.5 and 24 h after dosing the bitches or 0.5, 3.5,
7.5 h after suckling on day 28 and 0.5 h after suckling
on day 29. A sample was also taken before dosing the
bitch on day 27. Blood samples were collected from the
pups that were confirmed to be suckling milk about
30 min before the first blood collection time point. A
total of 4 pups per bitch (n = 24) was sampled. The tubes
were centrifuged at 3500 rpm for 10 min at 4 °C. The re-
sultant plasma collected from bitches was separated,
transferred into 3 uniquely labelled clear polypropylene
tubes (at least 500 μL of plasma per aliquot), and placed
in a −80 °C deep freezer. There was only 1 plasma ali-
quot fraction for the pups.
Milk samples were collected manually from the mam-
mary gland of the bitches into polypropylene tubes. To
stimulate milk release, each bitch’s nipples were gently
stripped by repetitive stroking motions. Each bitch’s
mammary glands were either massaged or warmed with
a warm cloth. About 1.1 mL of milk was collected on
the following time points post dosing: 1, 2, 4, 8 and
24 h. On study days 0 and 1, a sample was taken from
each animal at each time point. On study days 28 and
29, some samples could not be taken because there was
not enough milk available. On study day 28, the first
milk sample was taken just prior first suckling within 1
to 4 min. After collection, samples were mixed gently
and separated, equally transferred into 2 uniquely la-
belled clear polypropylene tubes (at least 500 μL of milk
per aliquot), and placed in a −80 °C deep freezer.
Sample analysis
The concentration of cimicoxib in the plasma samples
was determined according to a validated HPLC method
described in Jeunesse et al. [20]. Briefly, cimicoxib was
extracted by a solid liquid extraction process using HLB
Oasis cartridges (Waters). Separation was achieved by a
reverse phase column with an octadecylsilane stationary
phase (Merck Lichrospher 100 RP18e (125x4) mm,
5 μm) using a guard column (Merck Lichrospher 100
RP18e (4x4) mm, 5 μm). UV detection was performed at
242 nm. Within-day and day-to-day coefficients of vari-
ation were less than 9 % and the accuracy ranged from
94 to 103 %. The limit of quantification of the method
was 0.01 μg/mL. For the milk samples, the method was
validated using cow milk as blank matrix. Only the ex-
traction was altered using dichloromethane as an
extracting solvent. The specificity of the method was
tested against co-extracted milk impurities and against
demethylated cimicoxib which is the major metabolite of
cimicoxib [30]. The limit of quantification in the milk
samples was 0.03 μg/mL. Within-day and day-to-day co-
efficients of variation were less than 7 % and the accur-
acy ranged from 96 to 105 %.
Pharmacokinetic evaluation
The individual plasma data sets were submitted to a non
compartmental analysis by means of the WinNonlin®
software (version 5.0.1). Actual doses of cimicoxib (mg/
kg) and actual blood sampling times were used for the
analyses. The best-fitting slopes of the terminal phase,
λz, were computed by log-linear regression using the
best adjusted R-square with at least three time points
(excluding the Cmax). Area Under the Curve (AUC)
values were computed using the Linear Trapezoidal, Lin-
ear Interpolation rules. The main pharmacokinetic pa-
rameters were calculated. The following parameters
obtained on D0 and on D28 were compared using paired
t tests with a significance threshold of 5 %: Cmax, Tmax,
T½λz, AUCINF and Cl_F.
Only the milk data sets collected on D0 were sub-
mitted to a non compartmental analysis. There were
not enough samples collected on D28 for performing
a pharmacokinetic analysis. The same rules for non
compartmental analysis (plasma samples) were applied
to the milk samples. The last elimination slope, λz,
was not calculated because there were not enough
time points.
Abbreviations
COX: Cyclo-oxygenase; HPLC: High performance liquid chromatography;
NSAID: Non steroidal anti-inflammatory drug; Rpm: Round per minute;
SD: Standard deviation; UK: United Kingdom; UV: Ultra-violet.
Competing interests
M. Schneider, F. Dron and F. Woehrlé are employees of Vétoquinol SA.The
experimental test site was Charles River Preclinical Services, Ballina, Ireland
and the study was sponsored by Vétoquinol SA.
Author’s contributions
MS conceived of the study, drafted its design, performed the pharmacokinetic
analysis, analysed the obtained results and drafted the manuscript. FD
participated in the design of the study, performed the analytical work and
helped to draft the manuscript. FW participated in the conception of the study,
participated in the design of the study and helped to draft the manuscript. AK
participated in the design of the study, coordinated the animal phase and
helped to draft the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
We thank the technical staff of Charles River Ballina Ireland for their skilled
work during the animal phase. We thank also the staff of the Bioanalysis Unit
of Vétoquinol for their involvement in the analytical work.
Author details
1Vétoquinol Global Development, 70200 Lure, France. 2Crosspatrick, Killala,
Co. Mayo, Ireland.
Received: 15 January 2015 Accepted: 16 July 2015
Schneider et al. BMC Veterinary Research  (2015) 11:178 Page 5 of 6
References
1. Raffe MR, Carpenter RE. Anesthetic management of caesarean section
patients. In: Tranquilli WJ, Thurmon JC, Grimm KA, editors. Lumb and Jone’s
Veterinary Anesthesia and Analgesia. 4th ed. Ames: Blackwell Publishing;
2007. p. 955–69.
2. Lohuis JA, van Werven T, Brand A, van Miert AS, Rohde E, Ludwig B, et al.
Pharmacodynamics and pharmacokinetics of carprofen, a non-steroidal
anti-inflammatory drug, in healthy cows and cows with Escherichia coli
endotoxin-induced mastitis. J Vet Pharmacol Ther. 1991;14(3):219–29.
3. Malreddy PR, Coetzee JF, Kukanich B, Gehring R. Pharmacokinetics and
milk secretion of gabapentin and meloxicam co-administered orally in
Holstein-Friesian cows. J Vet Pharmacol Ther. 2013;36(1):14–20.
4. De Graves FJ, Riddell MG, Schumacher J. Ketoprofen concentrations in
plasma and milk after intravenous administration in dairy cattle. Am J Vet
Res. 1996;57(7):1031–3.
5. Anderson KL, Neff-Davis CA, Davis LE, Bass VD. Pharmacokinetics of flunixin
meglumine in lactating cattle after single and multiple intramuscular and
intravenous administrations. Am J Vet Res. 1990;51(9):1464–7.
6. Bergh MS, Budsberg SC. The Coxib NSAIDs: potential clinical and
pharmacologic importance in veterinary medicine. J Vet Intern Med.
2005;19:633–43.
7. McDonnell NJ, Keating ML, Muchatuta NA, Pavy TJ, Paech MJ. Analgesia
after caesarean delivery. Anaesth Intensive Care. 2009;37(4):539–51.
8. Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy
and the initiation of lactation. Anesth Analg. 2013;116(5):1063–75.
9. Huang YC, Tsai SK, Huang CH, Wang MH, Lin PL, Chen LK, et al. Intravenous
tenoxicam reduces uterine cramps after Cesarean delivery. Can J Anaesth.
2002;49(4):384–7.
10. Facchinetti F, De Pietri R, Giunchi M, Genazzani AR. Use of meclofenamic
acid in gynecology and obstetrics: effects on postsurgical stress. Clin J Pain.
1991;7(Suppl 1):S60–3.
11. Rorarius MG, Suominen P, Baer GA, Romppanen O, Tuimala R. Diclofenac
and ketoprofen for pain treatment after elective caesarean section. Br J
Anaesth. 1993;70(3):293–7.
12. Munishankar B, Fettes P, Moore C, McLeod GA. A double-blind randomised
controlled trial of paracetamol, diclofenac or the combination for pain relief
after caesarean section. Int J Obstet Anesth. 2008;17(1):9–14.
13. Bourlert A. Diclofenac intramuscular single dose to decrease pain in post
operative Caesarean section: a double blind randomized controlled trial.
J Med Assoc Thai. 2005;88(1):15–9.
14. Lowder JL, Shackelford DP, Holbert D, Beste TM. A randomized, controlled
trial to compare ketorolac tromethamine versus placebo after cesarean
section to reduce pain and narcotic usage. Am J Obstet Gynecol.
2003;189(6):1559–62.
15. Al-Waili NS. Efficacy and safety of repeated postoperative administration of
intramuscular diclofenac sodium in the treatment of post-cesarean section
pain: a double-blind study. Arch Med Res. 2001;32(2):148–54.
16. Olofsson CI, Legeby MH, Nygårds EB, Ostman KM. Diclofenac in the
treatment of pain after caesarean delivery. An opioid-saving strategy.
Eur J Obstet Gynecol Reprod Biol. 2000;88(2):143–6.
17. Paech MJ, Salman S, Ilett KF, O’Halloran SJ, Muchatuta NA. Transfer of
parecoxib and its primary active metabolite valdecoxib via transitional
breastmilk following intravenous parecoxib use after cesarean delivery:
a comparison of naive pooled data analysis and nonlinear mixed-effects
modeling. Anesth Analg. 2012;114(4):837–44.
18. Kim TW, Della Rocca G, Di Salvo A, Ryschanova R, Sgorbini M, Giorgi M.
Evaluation of pharmacokinetic and pharmacodynamic properties of
cimicoxib in fasted and fed horses. NZ Vet J. 2015;63(2):92–7.
19. Kim TW, Della Rocca G, Di Salvo A, Owen H, Sgorbini M, Giorgi M.
Pharmacokinetics of the novel cyclooxygenase 2 inhibitor cimicoxib in
donkeys. J Equine Vet J. 2014;34:923–5.
20. Jeunesse EC, Schneider M, Woehrlé F, Faucher M, Lefebvre HP, Toutain P-L.
Pharmacokinetic/pharmacodynamic modelling for the determination of a
cimicoxib dosing regimen in the dog. BMC Veterinary Research.
2013;9(250):1–15.
21. Begg EJ. Determinants of drug transfer into human milk. In: Bennet PN,
editor. Drugs and human lactation. 2nd ed. Amsterdam: Elsevier Science;
1996. p. 50–2.
22. Martinez M, Modric S. Patient variation in veterinary medicine: part I. Influence
of altered physiological states. J Vet Pharmacol Ther. 2010;33:213–26.
23. Kim TW, Lebkowska-Wieruszewska B, Owen H, Yun HI, Kowalski CJ, Giorgi M.
Pharmacokinetic profiles of the novel COX-2 selective inhibitor cimicoxib in
dogs. Vet J. 2014;200:77–81.
24. Oftedal OT. Lactation in the dog: milk composition and intake by puppies.
J Nutr. 1984;114:803–12.
25. Jenness R. The composition of human milk. Semin Perinatol. 1979;3:225–39.
26. Jensen RG, Hagerty MM, MacMahon KE. Lipids of human milk and infant
formulas: a review. Am J Clin Nutr. 1978;31:990–1016.
27. Giorgi M, Saccomanni G, Del Carlo S, Manera C, Lavy E. Pharmacokinetics of
intravenous and intramuscular parecoxib in healthy Beagles. Vet J.
2012;193:246–50.
28. Alsalameh S, Burian M, Mahr G, Woodcock BG, Geisslinger G. Review
article: the pharmacological properties and clinical use of valdecoxib, a
new cyclo-oxygenase-2 selective inhibitor. Aliment Pharmacol Ther.
2003;17:489–501.
29. Huggins RA, Deavers S, Smith EL. Growth in Beagles: changes in body
weight, plasma volume, and venous hematocrit. Pediat Res. 1971;5:193–8.
30. Anonymous. EMEA/V/C/000162. In: Cimalgex: EPAR – Product Information,
Annex I – Summary of product characteristics. London: European Medicines
Agency, Veterinary Medicines; 2011.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Schneider et al. BMC Veterinary Research  (2015) 11:178 Page 6 of 6
